by Dan Roberts February 2006 Dr. Jayakrishna Ambati (University of Kentucky HealthCare physician and Associate Professor and Vice Chair of the Department of Ophthalmology and Visual Sciences), has announced that his lab has identified fragments of two known components of drusen that may be the cause of dry age-related macular degeneration (AMD) progressing to the [Read More]
Author: droberts
Gene Therapy Successful in Halting CNV
by Dan Roberts Researchers have been able to halt (at least temporarily) choroidal neovascularization (CNV) with gene replacement therapy. This was done by single injections into the eyeballs of patients during a phase I clinical trial. Here is more detail, as reported on January 17, 2006 by Genetic Engineering News (www.genengnews.com): Clinical Trial on Gene [Read More]
SmartSight: Making the Most of Remaining Vision
Information for Patients from the American Academy of Ophthalmology (Reprinted with permission) Is it difficult for you to read the newspaper, see price tags or set dials? Are you bothered by glare? If you answered “yes” to any of these, then SmartSight is for you. Making the most of the vision you have is smart. [Read More]
Bacterial Infection Linked to AMD
by Dan Roberts (Updated November 13, 2005) According to a report in the April 2003 issue of the Archives of Ophthalmology (2003;121:478-482.), the bacterium Chlamydia pneumoniae may lead to a higher risk of age-related macular degeneration (AMD). The researchers found that people with AMD tend to carry higher levels of antibodies targeted against C. pneumoniae, [Read More]
Biocurrent Therapy: A Promising Treatment for Dry AMD
by Dan Roberts with additional material by Wendy Strouse Watt, O.D. Originally Published October 26, 2005 Acuity Medical has successfully completed a proof of concept, double-masked trial of its TheraMac™ device for the treatment of dry age-related macular degeneration (AMD). The therapy developed from early studies of microcurrent stimulation, with improvements in the science and [Read More]